GSA Capital Partners LLP Sells 78,496 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

GSA Capital Partners LLP lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 153,239 shares of the company’s stock after selling 78,496 shares during the quarter. GSA Capital Partners LLP’s holdings in Cellebrite DI were worth $2,581,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CLBT. Janney Montgomery Scott LLC raised its stake in Cellebrite DI by 240.1% in the first quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock valued at $502,000 after purchasing an additional 31,981 shares in the last quarter. SG Americas Securities LLC raised its stake in Cellebrite DI by 34.8% during the first quarter. SG Americas Securities LLC now owns 51,881 shares of the company’s stock worth $575,000 after acquiring an additional 13,392 shares in the last quarter. Sei Investments Co. raised its stake in Cellebrite DI by 44.7% during the first quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock worth $1,343,000 after acquiring an additional 37,408 shares in the last quarter. Inspire Investing LLC acquired a new position in Cellebrite DI during the first quarter worth about $862,000. Finally, Russell Investments Group Ltd. raised its stake in Cellebrite DI by 92.5% during the first quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company’s stock worth $188,000 after acquiring an additional 8,001 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $18.37 on Tuesday. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of -11.85, a PEG ratio of 2.52 and a beta of 1.50. Cellebrite DI Ltd. has a 52-week low of $7.32 and a 52-week high of $21.00. The stock’s 50 day moving average price is $17.62 and its two-hundred day moving average price is $14.34.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.09 EPS. On average, equities research analysts forecast that Cellebrite DI Ltd. will post 0.31 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. Bank of America boosted their target price on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. TD Cowen boosted their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Lake Street Capital boosted their price target on Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Craig Hallum upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.